Thymosin beta-4 (TB-4): A naturally occurring protein found in blood platelets, TB-4 plays a role in the repair and regeneration of injured tissues in the human body. It was first detected in the thymus, a gland that produces white blood cells. While it’s recently been used to treat horses and implicated in horse doping, it’s also found its way into bodybuilding circles. While there is no published evidence that TB-4 produces any benefit to athletes, it was added to the WADA banned substances list in 2011.
Aging often comes with many undesirable effects on our bodies including increased fat, decreased muscle muscle mass and low energy. Some of these issues can be caused by adult growth hormone deficiency. Peptide therapies provide a healthy option to reinvigorate the natural release of growth hormone in the body and reverse the negative effects of aging.
If there's one thing that science has definitively said about AOD9604, it is that it is safe and has no side effects. Calzada, after trying the peptide out as an anti-obesity and anti-arthritic, has succeeded in having the peptide declared "Generally regarded as safe" by the FDA, which makes it legal to use as a food additive in America. Calzada, seemingly under no pretense that their product has pharmaceutical properties, is now trying to break into the US over the counter supplement and "Nutraceutical" market with AOD9604 (2,4). Interestingly, the compound has only been approved for use in levels of up to 1mg per day (2), whereas the doses used in trials generally hovered around 500ug/kg (5,6), which means a 100kg person was receiving 50mg of the peptide daily. There is no science behind the peptide, or the dosage, and Calzada themselves have previously said AOD9604 is not effective orally (2).
Ghrelin and GH secretagogues, including GH-releasing peptide (GHRP)-6, stimulate food intake and adiposity. Because insulin modulates the hypothalamic response to GH secretagogues and acts synergistically with ghrelin on lipogenesis in vitro, we analyzed whether insulin plays a role in the metabolic effects of GHRP-6 in vivo. Streptozotocin-induced diabetic rats received saline, GHRP-6, insulin, or insulin plus GHRP-6 once daily for 8 wk. Rats receiving saline suffered hyperglycemia, hyperphagia, polydipsia, and weight loss. Insulin, but not GHRP-6, improved these parameters (P < 0.001 for all), as well as the diabetes-induced increase in hypothalamic mRNA levels of neuropeptide Y and agouti-related peptide and decrease in proopiomelanocortin. Cocaine amphetamine-related transcript mRNA levels were also reduced in diabetic rats, with GHRP-6 inducing a further decrease (P < 0.03) and insulin an increase. Diabetic rats receiving insulin plus GHRP-6 gained more weight and had increased epididymal fat mass and serum leptin levels compared with all other groups (P < 0.001). In epididymal adipose tissue, diabetic rats injected with saline had smaller adipocytes (P < 0.001), decreased fatty acid synthase (FAS; P < 0.001), and glucose transporter-4 (P < 0.001) and increased hormone sensitive lipase (P < 0.001) and proliferator-activated receptor-gamma mRNA levels (P < 0.01). Insulin normalized these parameters to control values. GHRP-6 treatment increased FAS and glucose transporter-4 gene expression and potentiated insulin's effect on epididymal fat mass, adipocyte size (P < 0.001), FAS (P < 0.001), and glucose transporter-4 (P < 0.05). In conclusion, GHRP-6 and insulin exert an additive effect on weight gain and visceral fat mass accrual in diabetic rats, indicating that some of GHRP-6's metabolic effects depend on the insulin/glucose status.
In addition, scientists have observed that those who supplemented with IGF-1 experienced a preponderance of new brain cell growth and new muscle mass and new studies confirmed this to be true, even among individuals with both brain damage and muscle-wasting sarcopenia. Furthermore, research studies have found IGF-1 to increase feelings of youthfulness, improve well-being, and even to alleviate depression.
CJC-1295 and Mod GRF 1-29 are administered in micrograms (mcg) rather than milligrams (mg) – the unit of administration of other steroids and performance-enhancing drugs. It has also been found that a 100mcg dose is enough to fully saturate the receptors in the anterior pituitary. This is called the saturation dose. After a dose of 100mcg has been administered, the subsequent dosages will achieve only half the effect.
In total 118 AEs were reported. No SAEs were reported. The most common adverse event reported by 16/23 subjects (69.6%) was mild or moderate headache. From all the reported AEs three events were reported of severe intensity (one in the 50 µg/kg AOD9604 group, 2 in the placebo group), with one of those events (a feeling of chest tightness) deemed possibly related to the AOD9604 treatment. Mild or moderate euphoria deemed possibly related to treatment, was reported by 5/23 subjects, during the periods when the AOD9604 was administered. There were no reports of euphoria during placebo administration. In total, there was no observable trend between the different treatment groups with respect to the incidence of certain AEs.
Plasma Nt‐proANP levels were measured by ELISA (proANP 1‐98; Biomedica Medizinprodukte GmbH & Co KG, Austria). Plasma Nt‐proBNP levels were measured using an electrochemiluminescence immunoassay (Elecsys proBNP; Roche, Indianapolis, IN). Mature ANP was measured using an in‐house immunoassay at the Mayo Clinic (Rochester, MN; J. Burnett). Mature BNP was measured by immunoassay (Siemens, New York, NY). Intra‐assay coefficients of variation were <10% for all assays.
Very tough to say. I am not a doctor and this is not to be taken, interpreted or construed as medical advice. Please talk with a licensed medical professional about this. These are just my own personal thoughts and not a prescription or a diagnosis or any form of health care whatsoever. I could possibly help but would need to see your health history, blood, biomarkers, etc. I'd be happy to help you via a personal one-on-one consult. Just go to https://bengreenfieldfitness.com/coaching. and then choose a 20 or 60 minute consult, whichever you'd prefer. I can schedule ASAP after you get that.
At both visits, saline infusion was associated with a significant increase in left ventricular (LV) end‐diastolic volume (P=0.001 for saline effect), whereas LV end‐systolic volume was unchanged. Stroke volume and cardiac output increased in response to saline administration at both pre‐ and post‐bypass visits. The effect of saline infusion on cardiac function did not differ before and after surgery (saline×surgery interaction P values non‐significant).
To put this into simple terms, collagen protein promotes fullness and keeps our body feeling satisfied after a meal. If we feel more full for a longer time after eating, we are less likely to overeat at the next meal. This goes hand in hand with fighting off pesky cravings. We know how difficult it can be to fight cravings, such as those for salty, oily or fatty foods. And not to mention sugary foods, which our brain can actually get addicted to. Including collagen into your daily diet can help in the battle against cravings and weight loss by keeping you full and satisfied.
One of the biggest concerns many of us have as we get older is: weight management. Maintaining a healthy weight is a lifelong struggle for many and can get harder as we get older. In fact, statistics show that 70% of American adults are overweight, and half of those adults are obese. We need to find ways to lose weight in a healthy manner, and more importantly keep off the weight, long-term. Ongoing research about collagen, a natural and unique type of protein, shows that collagen supplementation just might be the key in your journey to stay at a healthy weight and better your health.
The second long-term study (METAOD006) was a randomized, double-blind, placebo-controlled, multi-center, parallel group study conducted at 16 Australian hospitals and medical centres. In that study 534 were enrolled but of those 502 clinically obese subjects (BMI ≥ 30 kg/m2 and ≤ 45 kg/m2; Median BMI: 36.3 kg/m2, range: 30 to 45.2 kg/m2; 44% males and 56% females) were randomized to receive a daily dose of 0.25, 0.5 or 1mg AOD9604 or placebo for 24 weeks. Prior to this treatment period all subjects underwent a 4-week single-blind placebo run-in period. After cessation of the treatment a 4-week follow-up phase was performed.
To receive further information and prices of Peptides You will need to complete a simple online medical questionnaire. This is a legal requirement due to the regulation of Peptides in Australia. We cannot legally advertise specific Peptides to the general public without first ascertaining you are over 18 years of age and have submitted the required medical records.